About Us

VAXMED is an Australian biotechnology company designing, developing and manufacturing next-generation vaccines for unmet medical needs.  With our new technology enabling us to make safe and effective vaccines in record time and on an unprecedented scale.

Our technology allows us to standardize the way vaccines are created and  manufactured.  Our platform technology utilises a viral vaccine delivery vehicle encoding for antigens from any infectious disease to create an instant vaccine in a short period of time without the need for  inactivation or attenuation of the original pathogen.

Unlike subunit vaccines which are  proteins used as vaccine antigens, our vaccines do not require the addition of adjuvants as  the vehicle is self-adjuvanting  and potent enough to be used in single administration  vaccination strategies.  

Our vaccines are safe, immunologically potent, stable at  refrigerator temperatures, can be freeze-dried, can be rapidly manufactured and cost  effectively scaled-up for use in both epidemic response and routine vaccination.

Our business model is to develop our products through into human clinical trials, and to attract co-development partnerships or licensing arrangements all the way through to  commercialization.